PROSE Treatment

Ocular Chronic GVHD

 “My bone marrow transplant gave me back my life. But I wasn’t able to enjoy that life until I got PROSE treatment.”
— GVHD patient

76% of patients with ocular complications from GVHD reported significant success with BostonSight® PROSE treatment.

Contact us today to see if we can help you!

Download our guide here:
Dry Eye and GVHD: BostonSight PROSE Treatment Can Help

About Ocular Chronic GVHD

Graft-versus-host disease (GVHD) is a common side effect of an allogeneic (donor source) bone marrow, stem cell or cord blood transplant (BMT) - approximately half of people who receive allogeneic transplants develop chronic GVHD. GVHD is an autoimmune disease that can affect many different parts of the body; the skin, eyes, mouth, stomach and intestines are affected most often. GVHD can range from mild to life-threatening.

Ocular GVHD is a major complication that affects 60% - 80% of patients with chronic GVHD. Eye related symptoms include blurry vision, foreign body sensation, burning sensation, severe light sensitivity, chronic conjunctivitis (pink eye), dry eyes and eye pain.

How BostonSight PROSE Treatment Can Help

Hundreds of patients with dry eye and other ocular complications from graft versus host disease -just like you- have had their vision and visual function restored and quality of life transformed with our innovative treatment: PROSE. BostonSight PROSE (prosthetic replacement of the ocular surface ecosystem) treatment uses FDA-approved customized prosthetic devices to replace or support impaired ocular surface system functions that protect and enable vision.

Device schematic - white

The prosthetic devices created during PROSE are transparent domes, about the size of a nickel. They look similar to an oversized hard contact lens and resemble a margarita glass without the stem in shape. PROSE devices fit under the eyelids, vaulting the damaged cornea and resting on the sclera (the relatively insensitive white tissue of the eye). Worn during waking hours, patients are trained in daily application, removal and cleaning as part of the treatment process.

PROSE devices are made out of a highly gas-permeable hard plastic that allows oxygen to reach the cornea. They are designed to create a space between the prosthetic device and the eye that is filled with sterile saline. The liquid remains in the reservoir, providing constant lubrication by bathing the eye in a pool of artificial tears.

Benefits of BostonSight PROSE

  • Reduces ocular chronic GVHD symptoms of pain and light sensitivity and supports healing by restoring a healthy ocular surface environment
  • Improves blurry vision by masking irregularities on the cornea’s surface and transmitting a sharp image to the back of the eye
  • Prevents further damage by protecting and shielding the cornea against the environment and eyelids

Note: The prosthetic devices used in PROSE were formerly known as Boston Ocular Surface Prosthesis (BOS-P), Boston Scleral Lens devices and Boston Scleral Lens Prosthetic Devices. 

Updated 7/15

Female patient applies her PROSE device

GVHD Symptoms and Treatment Success

A 2010 BostonSight survey of 51 people with ocular chronic GVHD found that:

  • 96% had moderate or severe eye pain
  • 87% had difficulty reading regular print newspapers, magazines or websites
  • 80% had difficulty with work or hobbies that require seeing up close
  • 77% had light sensitivity
  • 75% had difficulty driving at night

When asked about their success with various treatments:

  • 0% had significant success with oral antibiotics, fish or flaxseed oils
  • 0% with punctal plugs
  • 0% with topical immunosuppression (Restasis/Cyclosporine)
  • 0% with topical steroids
  • 7% with artificial tears, lubricant gels or ointments

76% had significant success with BostonSight® PROSE treatment

* Survey questions refer to success with Boston Ocular Surface Prosthesis (BOS-P) and Boston Scleral Lenses used exculsively in BostonSight PROSE treatment.

Read more patient survey results in our Report Back to the Community.


Cancer survivor and PROSE patient Meghan

Unfortunately, like many of the people who receive allogeneic stem cell transplants, Meghan developed ocular graft-versus-host disease about a year after her transplant. For the stay-at-home Mom of three active children, the disease was more